TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03516474

Intervention type: DEVICE
Intervention: MIMOSA Diagnostics
Description: The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing.

Intervention type: DEVICE
Intervention: MIMOSA Diagnostics
Description: The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing.

Intervention type: DEVICE
Intervention: MIMOSA Diagnostics
Description: The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing.

Intervention type: DEVICE
Intervention: MIMOSA Diagnostics
Description: The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing.
Study: NCT00321087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Dose escalation from 600 to 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Placebo followed by T2000 dose escalation from 600 to 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Placebo followed by dose escalation from 600 to 1000
Study: NCT02661178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside (BAY 44-4400)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04834960

Intervention type: OTHER
Group type: OTHER
Intervention: Minimizing Missed Opportunities for Vaccination (MOV)
Description: This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
Study: NCT03810729

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone assessment
Description: The smartphone app will be performed on participants randomly assigned to receive this test.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Allen's Test
Description: The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
Study: NCT01369329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 ustekinumab 130 mg
Description: Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: ustekinumab approximately 6 mg/kg
Description: Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Form=solution for injection, route=intravenous use, in a single dose.
Study: NCT03206788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
Study: NCT02325973

Intervention type: DEVICE
Group type: OTHER
Intervention: PressureWire Certus guidewire
Description: Assessment of IMR index in coronaries through PressureWire Certus guidewire
Study: NCT02891928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocker sole shoes
Description: Measure of walk testing Measure of standing position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal shoes
Description: Measure of walk testing Measure of standing position
Study: NCT00076453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge orthotic shoe inserts
Description: Customized lateral wedge orthotic shoe inserts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthotic shoe inserts
Description: Neutral orthotic inserts
Study: NCT00947791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: a single IV infusion of ketamine, IV 0.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: a single IV infusion of ketamine, IV 0.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: a single IV infusion of midazolam, 0.045 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: a single IV infusion of midazolam, 0.045 mg/kg
Study: NCT00547001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Study: NCT00917644

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single 80 mg dose of marketed 80 mg atorvastatin tablets

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A single dose of new formulation of 80 mg atorvastatin tablets
Study: NCT00645255

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo one capsule daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sibutramine or placebo
Description: one capsule daily
Study: NCT02045030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept + FOLFIRI
Description: Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
Study: NCT00590928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 40mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranitidine
Description: 50mg every h hours
Study: NCT04169971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Played through headphones during the operation under spinal anaesthesia
Study: NCT04716556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
Study: NCT04062136

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Transplantation of umbilical cord mesenchymal stem cells
Study: NCT02156245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation program (including concentric cycle ergometer)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling included into a conventional rehabilitation program
Study: NCT04982003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
Study: NCT03774823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF and PEMF
Description: RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
Study: NCT02150031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlorhexidine
Description: mouthwash with 10 ml for 1 minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Chlorhexidine
Description: subgingival irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Chlorhexidine
Description: supragingival irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: dental extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: dental extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: dental extraction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tooth extraction
Description: dental extraction
Study: NCT02034123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
Study: NCT03831087

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR-CMR
Description: CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR-CT
Description: CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
Study: NCT00882414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FERINJECT® (Ferric carboxymaltose)
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FERINJECT® (Ferric carboxymaltose)
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FERINJECT® (Ferric carboxymaltose)
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
Study: NCT05347615

Intervention type: PROCEDURE
Intervention: IOL Implantation:EDOF lens
Description: A EDOF lens is implanted in the dominant eye

Intervention type: PROCEDURE
Intervention: IOL Implantation: Monofocal lens
Description: A monofocal lens is implanted in the non dominant eye.
Study: NCT01411787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
Study: NCT03773952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: oral small molecule, antagonist of Adenosine A3 receptor (AA3R)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsules
Study: NCT04672083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT31
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT31
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT31
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT31
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT05623566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
Study: NCT04351412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma
Description: Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
Study: NCT03558945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen vaccine
Description: Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
Study: NCT03495622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Text messaging
Description: The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial
Study: NCT03774823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
Study: NCT04351412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma
Description: Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma
Description: Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
Study: NCT01718886

Intervention type: DEVICE
Intervention: Obalon Gastric Balloon
Study: NCT03767361

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cells transfusion
Description: packed red blood cells transfusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cells transfusion
Description: packed red blood cells transfusion
Study: NCT01271686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost
Description: 0.01% bimatoprost once in the evening for 4 weeks
Study: NCT01070420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FFR via central venous line
Description: Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR via peripheral venous line
Description: Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
Study: NCT00717730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
Study: NCT00688363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: weekly blood glucose profile
Description: once daily self-control of urinary-glucose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: weekly blood glucose profile
Description: once daily self-control of urinary-glucose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three-monthly haemoglobin A1c
Description: once daily self-control of urinary-glucose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three-monthly haemoglobin A1c
Description: once daily self-control of urinary-glucose
Study: NCT00717730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.